NurExone Biologic Inc. (NRX.V)
| Previous Close | 0.6500 |
| Open | 0.6100 |
| Bid | 0.6100 x N/A |
| Ask | 0.6400 x N/A |
| Day's Range | 0.6100 - 0.6500 |
| 52 Week Range | 0.1850 - 1.1900 |
| Volume | |
| Avg. Volume | 177,948 |
| Market Cap | 42.78M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1100 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.98 |
GlobeNewswireNurExone Presenting on Revolutionary Spinal Cord Injury Therapy at European Conference on Exosomes and Regenerative Medicine
TORONTO and HAIFA, Israel, April 19, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, is pleased to announce that Dr. Lior Shaltiel, CEO and Director at NurExone, was invited to present on "Revolutionizing Spinal Cord Injury Treatment: Harnessing the Potential of Exosomes for Advanced Therapy in Comprehensive Approach" at the Exosomes of Europe conference in London in June, 2024. Dr. Shaltiel joins a
- GlobeNewswire
NurExone Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Company Update
TORONTO and HAIFA, Israel, April 02, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, developing regenerative medicine therapies, today provided a business update and reported financial results for the fourth quarter and financial year ended December 31, 2023. Fourth Quarter Highlights and Significant Milestones On October 26, 2023, the Company received a response from the Food and Drug Administratio
- GlobeNewswire
Gross Proceeds Close of $4M CAD Generated for NurExone From Warrants Exercise
TORONTO and HAIFA, Israel, March 27, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), is pleased to announce that, the Company completed a combined exercise and expiration of 12,682,340 common share purchase warrants issued pursuant to a private placement of units that closed on June 15, 2022. Following the Acceleration Event, as defined and further detailed in its press release dated September 28, 2023, 9,684,993 warrants were exercised a
